- Home
- HKIT vs BLRX Comparison
HKIT vs BLRX Comparison
Compare HKIT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HKIT | BLRX |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 12.6M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HKIT | BLRX |
|---|---|---|
| Price | $3.00 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 76.0K | 7.8K |
| Earning Date | 04-24-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $2.15 |
| 52 Week High | $8.80 | $4.56 |
Technical Indicators
Market Signals| Indicator | HKIT | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 50.99 |
| Support Level | $2.92 | $2.65 |
| Resistance Level | $3.59 | $3.02 |
| Average True Range (ATR) | 0.37 | 0.17 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 47.13 | 64.59 |
Price Performance
Historical ComparisonAbout HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.